These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2006-003682-14 Randomised phase II study on the treatment with pegfilgrastim after autologous blood stem cell transplantation 2014-01-25 due-trials
Not reported 2006-003683-54 Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbestrah... 2013-07-03 due-trials
Not reported 2007-001262-32 Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung canc... 2012-10-12 due-trials
Completed, but no date 2007-003945-33 A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. bad-data
Not reported 2008-001405-41 A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) 2013-02-28 due-trials
Completed, report not yet due 2008-003829-16 An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide co... 2016-10-24 not-yet-due
Ongoing 2008-004083-39 The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma not-yet-due
Completed, report not yet due 2009-010824-25 Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-dose... 2015-04-28 not-yet-due
Not reported 2009-014677-41 CHAMP – An open-label, randomised, multicentre, phase II clinical study of panitumumab plus pemetrexed and cisplatin (PemCisP) versus PemCis in the first-line treatment of patients with stage IIIB or ... 2013-11-05 due-trials
Not reported 2009-015119-42 An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versu... 2012-03-28 due-trials
Ongoing 2009-016782-28 Panitumimab in combination with radiotherapy in patients with locally advanced RAS wildtype rectal cancer (clinical stages II and III) not-yet-due
Not reported 2009-018025-73 Randomised phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- or third-line treatment of patients with metastatic breast cancer 2014-07-19 due-trials
Not reported 2010-018339-16 CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-posi... 2013-07-03 due-trials
Completed, but no date 2010-018849-59 A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in bad-data
Not reported 2010-019564-37 A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects with Metastatic Colorectal Carcinoma Receiving Panitumumab 2013-05-14 due-trials
Not reported 2010-023630-24 Phase II open-label pilot study evaluating the safety and efficacy of Certican ® (everolimus) in the prevention of chronic graft-versus-host disease and late pulmonary complications after allogeneic h... 2017-05-03 due-trials
Ongoing 2013-002564-69 Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapsed o... not-yet-due
Ongoing 2013-004328-12 Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial not-yet-due